BioMarin Pharma (BMRN) Reports In-Line Q2 EPS
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $59.97 --0%
EPS Growth %: -34.0%
Financial Fact:
INCOME FROM OPERATIONS: -60.09M
Today's EPS Names:
CCEL, FEIM, PLG, More
EPS Growth %: -34.0%
Financial Fact:
INCOME FROM OPERATIONS: -60.09M
Today's EPS Names:
CCEL, FEIM, PLG, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q2 GAAP EPS of ($0.21), in-line with the analyst estimate of ($0.21). Revenue for the quarter came in at $317.4 million versus the consensus estimate of $308.96 million.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Delta Air Lines (DAL) Tops Q2 EPS by 3c, Beats on Revenue; Offers Guidance
- AMD (AMD) PT Raised to $635 at Stifel as 'EPYC Server-CPU Franchise is an AI Winner'
- Helen of Troy (HELE) Tops Q1 EPS by 22c, Beats on Revenue; Offers FY Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
